PharmaCyte Biotech Inc. (PMCB)
NASDAQ: PMCBHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
PMCB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.27M
- EPS (TTM)
- -$2.31
- Dividend yield
- None
- 52-week range
- 0.3339 – 1.51
- Day range
- 0.39 – 0.4219
- Volume / Avg
- 214.13K / 205.72K
- Beta
- —
- Shares outstanding
- 10.74M
52-week range
PMCB stock today
On Oct 8, PMCB ended the session at $0.3974, shedding $0.0082 (2.02%), versus the S&P 500's 0.47% decline. At this level, PMCB sits near the bottom of its 52-week range of $0.3339 to $1.51: 73.7% below the high and 19.0% above the low. PharmaCyte Biotech has posted a net loss over the last twelve months (EPS of -$2.31), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About PharmaCyte Biotech
Company profilePharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Joshua N. Silverman
- Headquarters
- Las Vegas, NV
- Employees
- 2
- Website
- pharmacyte.com
PharmaCyte Biotech peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ERNAErnexa Therapeutics Inc. | 2.49 | +4.18% | $4.06M | vs PMCB |
| PPCBPropanc Biopharma Inc. | 0.471 | -5.55% | $4.63M | vs PMCB |
| EOCNEocene Ltd. | 3.62 | +4.69% | $3.87M | vs PMCB |
| NCNANuCana plc ADR | 1.13 | -0.88% | $4.70M | vs PMCB |
| CLDICalidi Biotherapeutics Inc. | 1.04 | +2.97% | $3.82M | vs PMCB |
| PCSAProcessa Pharmaceuticals Inc. | 1.35 | -4.93% | $3.77M | vs PMCB |
| GRIGRI Bio Inc. | 1.68 | -9.19% | $3.67M | vs PMCB |
| JUNSJupiter Neurosciences Inc. | 2.77 | -2.46% | $3.65M | vs PMCB |
Indexes, lists and sector
Appears in lists
PharmaCyte Biotech stock FAQ
What is PharmaCyte Biotech's stock price today?
PMCB last traded at $0.3974 as of Oct 8, 4:00 PM EDT, down 2.02% on the day. Prices are delayed at least 15 minutes.
Who is PharmaCyte Biotech's CEO?
Mr. Joshua N. Silverman is the chief executive officer of PharmaCyte Biotech Inc., which has about 2 employees.
What is the PMCB 52-week high?
The 52-week high for PMCB is $1.51 and the 52-week low is $0.3339. The stock is currently 73.7% below its high.